

In vitro reconstitution of the cyclosporine specific P450 hydroxylases using heterologous redox partner proteins

Yue Sun¹ · Li Ma² · Dongfei Han² · Lei Du² · Fengxia Qi² · Wei Zhang² · Jingran Sun² · Shan Huang¹ · Eung-Soo Kim³ · Shengying Li²

Received: 27 August 2016 / Accepted: 10 November 2016 / Published online: 25 November 2016
© Society for Industrial Microbiology and Biotechnology 2016

Abstract The cytochrome P450 enzymes (CYPs) CYP-sb21 from *Sebekia benihana* and CYP-pa1 from *Pseudonocardia autotrophica* are able to hydroxylate the immunosuppressant cyclosporin A (CsA) in a regioselective manner, giving rise to the production of two hair-stimulating agents (with dramatically attenuated immunosuppressant activity), γ -hydroxy-*N*-methyl-L-Leu4-CsA (CsA-4-OH) and γ -hydroxy-*N*-methyl-L-Leu9-CsA (CsA-9-OH). Recently, the in vitro activity of CYP-sb21 was identified using several surrogate redox partner proteins. Herein, we reconstituted the in vitro activity of CYP-pa1 for the first time via a similar strategy. Moreover, the supporting activities of a set of ferredoxin (Fdx)/ferredoxin reductase (FdR) pairs from the cyanobacterium *Synechococcus elongatus* PCC 7942 were comparatively analyzed to identify the optimal redox systems for these two CsA hydroxylases. The results suggest the great value of cyanobacterial redox partner proteins for both academic research and industrial application of P450 biocatalysts.

Keywords P450 hydroxylase · Cyclosporin A · Hair-stimulating agent · Redox partner proteins · *Synechococcus elongatus*

Introduction

Cytochrome P450 enzymes (CYPs) originated from actinomycetes play important roles in biosynthesis of diverse bioactive natural products [14] and bioconversion of xenobiotic compounds [3]. We have continuously been searching for biocatalysts that are capable of mediating the conversion from the immunosuppressant cyclosporin A (CsA) to the site-specific hydroxylation products γ -hydroxy-*N*-methyl-L-Leu4-CsA (CsA-4-OH) and γ -hydroxy-*N*-methyl-L-Leu9-CsA (CsA-9-OH) with significant hair-stimulating effects, but reduced immunosuppressive activity (Fig. 1) [6]. As part of these efforts, two P450 enzymes CYP-sb21 and CYP-pa1 were identified from *Sebekia benihana* and *Pseudonocardia autotrophica*, respectively [2, 7, 8]. Interestingly, in vivo bioconversion results [8] revealed that CYP-sb21 primarily hydroxylates the tertiary C–H bond of the side chain of the fourth methyl leucine, whereas CYP-pa1 exhibits preference for the ninth methyl leucine position. The protein sequence alignment of CYP-sb21 and CYP-pa1 showed 55/67% of identity/similarity. Recently, CYP-sb21 and CYP-pa1 were named CYP107Z14 and CYP107Z15, respectively, based on the nomenclature system developed by Nelson [12].

Most CYPs require redox partner proteins to sequentially transfer two electrons from NAD(P)H to their heme-iron reactive center for dioxygen activation [15]. The functionalities of many P450 enzymes have been identified; however, their physiologically associated redox partners remain largely unknown. Therefore, it often becomes

Y. Sun, L. Ma and D. Han contributed equally to this work.

✉ Eung-Soo Kim
eungsoo@inha.ac.kr

✉ Shengying Li
lishengying@qibebt.ac.cn

¹ College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, Shandong, China

² Shandong Provincial Key Laboratory of Synthetic Biology, CAS Key Laboratory of Biofuels, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, Shandong, China

³ Department of Biological Engineering, Inha University, Incheon, South Korea




Fig. 1 Bioconversion of CsA to CsA-4-OH and CsA-9-OH by CYP-sb21 or CYP-pa1 using cyanobacterial Fdx/FdR as redox partners

necessary to construct hybrid P450 reaction systems by using surrogate redox partners derived from heterologous hosts [18]. For example, Agematu et al. screened the activity of 213 bacterial CYPs in *Escherichia coli* and found 24 P450 enzymes that are able to stereoselectively hydroxylate testosterone by co-expressing the putidaredoxin gene *pdx* and the putidaredoxin reductase gene *pdR* from *Pseudomonas putida* ATCC17453 [1]. The oleic acid hydroxylation activity of CYP105D5 from *Streptomyces coelicolor* A3(2) could be supported by either Pdx/PdR from *P. putida* or flavodoxin/flavodoxin reductase (Fld/FIR) from *E. coli* [4]. Recently, we found that the P450 peroxygenase OleT_{JE} (CYP152L1) from *Jeotgalicoccus* sp. ATCC 8456 is capable of decarboxylating long-chain fatty acids to terminal alkenes when partnering with RhFRED from *Rhodococcus* sp. NCIMB 9784 [9] or Fld/FIR from *E. coli* [10]. Of particular importance, alternative redox partners not only influence catalytic efficiency and/or product distribution, but also could change the type and selectivity of P450 reactions [4, 10, 18].

The native preferred redox partner proteins of CYP-sb21 and CYP-pa1 remain unclear. Nonetheless, we successfully utilized the ferredoxin Fdx₁₄₉₉ and the ferredoxin reductase FdR₀₉₇₈ from the cyanobacterium type

strain *Synechococcus elongatus* PCC 7942 to reconstitute the in vitro activity of CYP-sb21 [11]. Interestingly, this cyanobacterial strain has at least seven different ferredoxin genes (*fdx_0338*, *fdx_0698*, *fdx_0814*, *fdx_0898*, *fdx_1499*, *fdx_1749*, and *fdx_2581*), as well as a single ferredoxin reductase gene (*fdR_0978*). Thus, in this study, we comparatively tested the ability of these Fdxs to support the in vitro activity of CYP-sb21 and CYP-pa1. As a result, these two analogous P450 enzymes showed distinct activity and regioselectivity against CsA when partnered by different Fdx/FdR pairs. Use of the optimal redox partners should enable development of better P450-based CsA bio-transformation systems.

Materials and methods

Materials

Antibiotics and bovine heart cytochrome *c* were obtained from Solarbio (Beijing, China). Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). The codon-optimized *cyp-sb21* and *cyp-pa1* were synthesized by Cosmo Genetech (Seoul, Korea), and six out of seven PCC

7942 ferredoxin genes (except *fdx_1499*) were synthesized by GENEWIZ (Beijing, China). The recombinant His-tagged proteins were purified using nickel–nitrilotriacetic acid (Ni–NTA) resin (Qiagen, Valencia, CA, USA), Amicon Ultra centrifugal filters (Merck Millipore, Billerica, MA, USA), and PD-10 desalting columns (GE Healthcare, Piscataway, NJ, USA). CsA, CsA-4-OH, and CsA-9-OH were prepared as previously reported [2, 8].

Construction of expression vectors

DNA manipulations were carried out by following standard procedures. The DNA sequences of *cyp-sb21* (GenBank Accession No. AGE14538), *cyp-pa1* (KJ433554), and *fdxs/fdR* (WP_011243487 for *fdx_0338*, WP_011243144 for *fdx_0698*, WP_011243037 for *fdx_0814*, WP_011377779 for *fdx_0898*, WP_011244794 for *fdx_1499*, WP_011244652 for *fdx_1749*, WP_011243839 for *fdx_2581* and WP_011242878 for *fdR_0978*) were retrieved from *S. benihana* KCTC9610, *P. autotrophica* KCTC9441, and *S. elongatus* PCC 7942, respectively. The pET28b-*cyp-sb21*, pET28b-*fdx_1499*, and pET28b-*fdR_0978*, were constructed previously [11]. The codon-optimized *cyp-pa1* gene was inserted between the restriction sites *NdeI/EcoRI* of pET-28b to afford pET-28b-*cyp-pa1*. The six synthesized *fdx* genes were individually subcloned into pET-28b (*NdeI/XhoI*). All constructs were confirmed through DNA sequencing by Sangon Biotech (Shanghai, China).

Expression, purification, and spectral characterization of CYP-sb21, CYP-pa1 and redox proteins

All recombinant His-tagged proteins were overexpressed in *E. coli* BL21 (DE3) and purified by Ni–NTA affinity chromatography [9]. The functional concentrations of CYP-sb21 and CYP-pa1 were determined by CO-bound reduced difference spectra using the extinction coefficient ($\epsilon_{450-490\text{nm}}$) of $91,000 \text{ M}^{-1} \text{ cm}^{-1}$ [13]. The Fdx and FdR concentrations were determined by Bradford assay using bovine serum albumin (BSA) as standard.

In vitro reconstitution of the CsA hydroxylation activity of CYP-sb21 and CYP-pa1

The standard reaction contained $10 \mu\text{M}$ P450 enzyme, $10 \mu\text{M}$ Fdx, $10 \mu\text{M}$ FdR, $200 \mu\text{M}$ CsA (diluted from 20 mM stock solution in methanol), 5 U glucose dehydrogenase (GDH) and 20 mM glucose as NADPH regeneration system [5], and 1 mM NADPH in $100 \mu\text{l}$ of reaction

buffer (50 mM NaH_2PO_4 , 10% glycerol, pH 7.4). The reaction was quenched by addition of $100 \mu\text{l}$ methanol after incubation at $30 \text{ }^\circ\text{C}$ for 16 h. The reaction samples were high-speed centrifuged to remove precipitated proteins, and the supernatants were analyzed by HPLC with an ODS HYPERSIL C18 reverse phase column ($5 \mu\text{m}$, $4.6 \times 150 \text{ mm}$, Thermo) in a gradient system consisting of 25% methanol in deionized water (solvent A) and 100% acetonitrile (solvent B). One cycle of buffer B gradient was programmed as follows: 45% B for 4 min, $45\text{--}61\%$ B over 16 min, $61\text{--}100\%$ B over 20 min, and 45% B for 5 min. The detection wavelength was 210 nm , and the flow rate was 1.0 ml/min .

LC-Q-TOF/MS analysis of products

Liquid chromatography-quadrupole time of flight mass spectrometry (LC-Q-TOF/MS) was recorded on a maXis UHR-TOF system (Bruker Daltonik, Germany) using a Thermo Scientific Hypersil GOLD column ($5 \mu\text{m}$, $2.1 \text{ mm} \times 100 \text{ mm}$) at $30 \text{ }^\circ\text{C}$ with $\text{H}_2\text{O} + 25\%$ MeOH as solvent A and acetonitrile as solvent B. The gradient elution profile was as follows: $0\text{--}4 \text{ min}$, 40% B; $4\text{--}15 \text{ min}$, $40\text{--}61\%$ B; $15\text{--}32 \text{ min}$, $61\text{--}100\%$ B; and $32\text{--}35 \text{ min}$, 40% B. The flow rate was set as 0.2 ml/min .

Results and discussion

Protein expression, purification and spectral characterization

The heterologous expression of two P450 genes, one FdR gene, and seven Fdx genes was conducted in *E. coli* BL21 (DE3). We were able to express CYP-sb21, CYP-pa1, FdR_0978, and Fdx_1499 in soluble form and in good quantities. However, direct expression of the native genes of *fdx_0338*, *fdx_0698*, *fdx_0814*, *fdx_0898*, *fdx_1749*, and *fdx_2581* led to non-expression or poor quantity of proteins. Thus, these DNA sequences were codon optimized to suit the codon preference of *E. coli*, by which the six *fdx* genes were successfully expressed and purified.

The CO-bound reduced difference spectra of CYP-sb21 and CYP-pa1 showed a characteristic peak at 450 nm , which was indicative of functional P450 enzymes (Fig. 2a, b). FdR_0978 displayed the typical UV–Vis spectrum of a ferredoxin reductase [17] with the local maximal peaks at 392 and 458 nm , and a pronounced shoulder at 492 nm (Fig. 2c).




Fig. 2 CO-bound reduced difference spectra of purified CYP-sb21 (a) and CYP-pa1 (b), and the UV-Vis absorption spectrum of FdR_0978 (c)

In vitro reconstitution of the activity of CYP-pa1 and CYP-sb21

In our previous study [11], the highest conversion of CsA by CYP-sb21 was achieved when using Fdx_1499 and FdR_0978 as redox partners. Since the protein sequence of CYP-pa1 is 55/67% identical/similar to that of CYP-sb21, we speculated that this redox partner system could also support the activity of CYP-pa1. As expected, CsA was converted into CsA-9-OH (5%) and CsA-4-OH (3%) by CYP-pa1/Fdx_1499/FdR_0978 in the presence of NADPH and the GDH/glucose based NADPH regeneration system, albeit in very low yield (Fig. 3). The identity of compounds was confirmed by comparison of their retention times with those of authentic standards and high resolution mass spectrometry (HRMS, Fig. 4). The in vitro hydroxylation site preference of CYP-pa1 is consistent with the previous in vivo results [2], confirming that this P450 enzyme is primarily a CsA-9-OH synthase. The low conversion ratio could be attributed to the high Fdx selectivity of CYP-pa1. Consistently, when CYP-pa1 was heterologously expressed in *Streptomyces coelicolor*, the conversion of CsA dramatically decreased relative to the same conversion in the native host *P. autotrophica*, which likely resulted from the lack of suitable redox partners [2]. The CsA hydroxylation catalyzed by CYP-sb21/Fdx_1499/FdR_0978 was analyzed as a control. Both CsA-4-OH (major product, 68% conversion) and CsA-9-OH (minor product, 19% conversion) were produced from CsA, which is consistent with the previous result [16].


The supporting activity of different cyanobacterial redox partners to CYP-pa1 and CYP-sb21

The low supporting activity of Fdx_1499/FdR_0978 to CYP-pa1 motivated the search for better redox partner proteins. Through genome mining, we found at least seven Fdx encoding genes (*fdx_0338*, *fdx_0698*, *fdx_0814*, *fdx_0898*, *fdx_1499*, *fdx_1749*, and *fdx_2581*) from the genome of *S.*

Fig. 3 HPLC analysis of CsA hydroxylation by CYP-sb21 (a) and CYP-pa1 (b) using different types of cyanobacterial Fdx paired with FdR_0978 as redox partners

elongatus PCC7942 (ASM1252v1). Upon expression and purification of the seven Fdxs and the single FdR_0978, we comparatively investigated the supporting activity of each Fdx (paired with FdR_0978), to CYP-pa1 and CYP-sb21. As shown in Fig. 3, all tested redox systems were capable of supporting the CsA hydroxylating activity of CYP-pa1 and CYP-sb21. However, no Fdxs supported the hydroxylating activity of CYP-pa1 well since the CsA conversion ratios only ranged from 3 to 18%. The optimal redox system for CYP-sb21 and CYP-pa1 turned out to be Fdx_1499/FdR_0978 (87% conversion) and Fdx_0338/FdR_0978 (18% conversion), respectively. For CYP-sb21, Fdx_0338 and Fdx_1749 also showed suboptimal activity. Taken together, the Fdx selectivity of CYP-pa1 appeared to be higher than that of CYP-sb21. These findings suggest that it could be more challenging to use heterologous redox partner proteins to engineer a CYP-pa1 based CsA-9-OH production system than we did for the CYP-sb21 based CsA-4-OH production system [11]. It is important to identify the native redox partner proteins from *P. autotrophica* to obtain the optimal activity of CYP-pa1, which is currently being investigated in our laboratories. Moreover, in all cases, CYP-pa1 and CYP-sb21 preferred hydroxylation at the ninth and the fourth *N*-methyl leucine, respectively, which indicates that the different choice of Fdx did not reverse the regioselectivity of these two CsA hydroxylases.

With respect to application potential, CsA-4-OH is a better hair growth promoter since it has a similar hair-stimulating effect; however, it has ten times less immunosuppressive activity than CsA-9-OH [16]. We previously conducted domain swapping between CYP-sb21 and CYP-pa1, and found that the second domain (135–228 amino acid) could affect the regioselectivity, and that swapping of this domain could increase the ratio of CsA-4-OH/CsA-9-OH






Fig. 4 High-resolution mass spectrometry (HRMS) of CsA-9-OH ($[M + Na]^+$: obs. 1240.8249, calc. 1240.8255 for $C_{62}H_{111}N_{11}O_{13}Na^+$), CsA-4-OH ($[M + Na]^+$: obs. 1240.8250, calc. 1240.8255), and CsA ($[M + Na]^+$: obs. 1224.8306, calc. 1224.8311 for $C_{62}H_{111}N_{11}O_{12}Na^+$)

[16]. The results of this and previous studies [11] indicate that the selection of Fdx could also change product distribution and total conversion. Taken together, these results have laid the foundation for engineering a strict P450 CsA-4-OH synthase for future industrial applications.

Acknowledgements This work was supported by National Natural Science Foundation of China under Grant Nos. NSFC 31422002 (S. Li) and 31300663 (D. Han), the Natural Science Foundation of Shandong Province, China (No. ZR2016CQ05) (L. Ma), and the National Research Foundation (NRF) of Korea (No. NRF-2014R1A2A1A11052236) (E.-S. Kim). We are grateful to the financial support from the Applied Basic Research Programs of Science and Technology of Qingdao (14-2-4-10-jch). We thank Prof. Xuefeng Lu at Qingdao Institute of Bioenergy and Biotechnology, Chinese Academy of Sciences, for providing us with the *S. elongatus* PCC7942 genome DNA.

References

- Agematu H, Matsumoto N, Fujii Y, Kabumoto H, Doi S, Machida K, Ishikawa J, Arisawa A (2006) Hydroxylation of testosterone by bacterial cytochromes P450 using the *Escherichia coli* expression system. *Biosci Biotechnol Biochem* 70:307–311

- Ban JG, Woo MW, Lee BR, Lee MJ, Choi SS, Kim ES (2014) A novel regiospecific cyclosporin hydroxylase gene revealed through the genome mining of *Pseudonocardia autotrophica*. *J Ind Microbiol Biotechnol* 41:879–886
- Bernhardt R (2006) Cytochromes P450 as versatile biocatalysts. *J Biotechnol* 124:128–145
- Chun YJ, Shimada T, Sanchez-Ponce R, Martin MV, Lei L, Zhao B, Kelly SL, Waterman MR, Lamb DC, Guengerich FP (2007) Electron transport pathway for a *Streptomyces cytochrome* P450: cytochrome P450 105D5-catalyzed fatty acid hydroxylation in *Streptomyces coelicolor* A3(2). *J Biol Chem* 282:17486–17500
- Hernandez-Martin A, von Buhler CJ, Tieves F, Fernandez S, Ferrero M, Urlacher VB (2014) Whole-cell biotransformation with recombinant cytochrome P450 for the selective oxidation of Grundmann's ketone. *Bioorg Med Chem* 22:5586–5592
- Kim SN AH, Lee CW, Lee MH, Kim JH, Kim JI, Kim SJ, Cho HS, Lee HS, Kim HJ (2004) The use of nonimmunosuppressive [γ -hydroxy-*N*-methyl-*L*-leucine4] cyclosporin derivatives for treating hair loss. Patent DE-1392224, WO02/092033 A1
- Lee MJ, Han K, Kim ES (2011) Targeted gene disruption and functional complementation of cytochrome P450 hydroxylase involved in cyclosporin A hydroxylation in *Sebekia benihana*. *J Microbiol Biotechnol* 21:14–19
- Lee MJ, Kim HB, Yoon YJ, Han K, Kim ES (2013) Identification of a cyclosporine-specific P450 hydroxylase gene through targeted cytochrome P450 complement (CYPome) disruption in *Sebekia benihana*. *Appl Environ Microbiol* 79:2253–2262
- Li S, Podust LM, Sherman DH (2007) Engineering and analysis of a self-sufficient biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain. *J Am Chem Soc* 129:12940–12941
- Liu Y, Wang C, Yan J, Zhang W, Guan W, Lu X, Li S (2014) Hydrogen peroxide-independent production of alpha-alkenes by OleT_{JE} P450 fatty acid decarboxylase. *Biotechnol Biofuels* 7:28
- Ma L, Du L, Chen H, Sun Y, Huang S, Zheng X, Kim ES, Li S (2015) Reconstitution of the in vitro activity of the cyclosporine-specific P450 hydroxylase from *Sebekia benihana* and development of a heterologous whole-cell biotransformation system. *Appl Environ Microbiol* 81:6268–6275
- Nelson DR (2009) The cytochrome P450 homepage. *Hum Genom* 4:59–65
- Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. *J Biol Chem* 239:2379–2385
- Podust LM, Sherman DH (2012) Diversity of P450 enzymes in the biosynthesis of natural products. *Nat Prod Rep* 29:1251–1266
- Ruettinger RT, Fulco AJ (1981) Epoxidation of unsaturated fatty acids by a soluble cytochrome P-450-dependent system from *Bacillus megaterium*. *J Biol Chem* 256:5728–5734
- Woo MW, Lee BR, Nah HJ, Choi SS, Li S, Kim ES (2015) Domain characterization of cyclosporin regio-specific hydroxylases in rare actinomycetes. *J Microbiol Biotechnol* 25:1634–1639
- Zhang J, Lu X, Li JJ (2013) Conversion of fatty aldehydes into alk (a/e)nes by in vitro reconstituted cyanobacterial aldehyde-deformylating oxygenase with the cognate electron transfer system. *Biotechnol Biofuels* 6:86
- Zhang W, Liu Y, Yan J, Cao S, Bai F, Yang Y, Huang S, Yao L, Anzai Y, Kato F, Podust LM, Sherman DH, Li S (2014) New reactions and products resulting from alternative interactions between the P450 enzyme and redox partners. *J Am Chem Soc* 136:3640–3646